Treatment of resected brain tumour beds using nanoparticle enhanced radiotherapy

使用纳米粒子增强放射治疗治疗切除的脑瘤床

• 批准号: 10032278
• 金额: $ 46.26万
• 依托单位: XERION HEALTHCARE LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10032278
• 关键词: Treatment; resected; brain; tumour; beds

Although great progress has been made in the treatment of some common cancers there remain many where there has been little improvement over decades. One of these is aggressive brain tumours, which have a median survival time of 14.6 months -- a figure that has not improved over the last four decades.The current best-supported care is surgery, which removes as much of the tumour as possible, followed by radiotherapy and chemotherapy. Cancer regularly reappears in this region and progresses rapidly.A unique nanoparticle loaded hydrogel will be developed which will release nanoparticles in areas of residual cancer. These nanoparticles improve the effectiveness of radiotherapy. This project will bring together Xerion Healthcare Ltd, a SME developing radiotherapy enhancing nanoparticles, and the Medicines Discovery Catapult (MDC), a CRO that specialises in pre-clinical development and imaging to develop a unique product that will enhance the effect of post-surgical radiotherapy on aggressive brain tumours and reduce the prospects of cancer regrowth.This project will enable Xerion to take the product forward to clinical trials. Given the critical clinical need for new treatments for this devastating disease, Xerion expects the rollout and uptake to be rapid.

虽然在治疗一些常见癌症方面取得了很大进展，但仍有许多癌症几十年来几乎没有改善。其中之一是侵袭性脑肿瘤，其中位生存时间为14.6个月--这一数字在过去40年里没有改善。目前最好的支持护理是手术，尽可能多地切除肿瘤，其次是放疗和化疗。癌症在该区域经常复发并迅速发展，将开发一种独特的纳米颗粒负载水凝胶，其将在残留癌症区域释放纳米颗粒。这些纳米粒子提高了放射治疗的有效性。该项目将使Xerion Healthcare Ltd（一家开发放射治疗增强纳米颗粒的中小企业）和Medicines Discovery Catapult（MDC）（一家专门从事临床前开发和成像的CRO）共同开发一种独特的产品，该产品将增强手术后放射治疗对侵袭性脑肿瘤的效果，并减少癌症再生长的可能性。该项目将使Xerion能够将该产品推向临床试验。鉴于对这种毁灭性疾病的新疗法的关键临床需求，Xerion预计推出和吸收将是迅速的。